Skip to content
Search

Latest Stories

PSNC presses for new approach to script switching

Pharmaceutical Services Negotiating Committee (PSNC) has raised concerns about the appropriateness of prescription switching during the Covid-19 pandemic.

Community pharmacy contractors have started to receive their FP34 Schedule of Payments relating to the dispensing of March and many have noticed a larger than usual number of switches listed.


During the pricing of prescriptions, if the pricing authority does not agree with the charge group (paid or exempt) in which a prescription has been submitted, the prescription will be ‘switched’.

If a declaration of exemption is required on the reverse of the form, but it has not been signed, the form is ‘switched’ to chargeable and a prescription charge is deducted from a contractor’s payment for each item on that form.

During the pandemic, many pharmacy teams have understandably been concerned about infection control, as per guidance issued by Public Health England (PHE) on the handling of paper prescriptions.

PSNC is pressing the DHSC and the NHS Business Services Authority (NHSBSA) to take a more pragmatic approach and review their processes around the switching of paper prescriptions with incomplete patient declarations.

PSNC has requested that such prescriptions are referred back to contractors or refunded.

Prior to the Covid-19 outbreak PSNC had proposed that all potential candidates for switching be referred back to the pharmacy for correction, however, this proposal was not accepted at the time.

Similarly, PSNC raised the collection of prescription charges during the Covid-19 pandemic as an unnecessary administrative burden and potential infection risk (through the handling of money) in discussions with the Government.

“We have also, with the British Medical Association (BMA) and Dispensing Doctors Association (DDA), written to the Secretary of State for Health and Social Care, Matt Hancock, to highlight this issue,” PSNC said.

“We will continue to press on both of these matters on behalf of community pharmacy contractors.”

More For You

Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less